Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.10
DGX's Cash-to-Debt is ranked lower than
92% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.52 vs. DGX: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
DGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: 0.44
Current: 0.1
0.02
0.44
Equity-to-Asset 0.46
DGX's Equity-to-Asset is ranked lower than
69% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. DGX: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
DGX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.45 Max: 0.56
Current: 0.46
0.3
0.56
Interest Coverage 8.87
DGX's Interest Coverage is ranked lower than
69% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.15 vs. DGX: 8.87 )
Ranked among companies with meaningful Interest Coverage only.
DGX' s Interest Coverage Range Over the Past 10 Years
Min: 5.74  Med: 7.97 Max: 9.27
Current: 8.87
5.74
9.27
Piotroski F-Score: 6
Altman Z-Score: 3.51
Beneish M-Score: -2.61
WACC vs ROIC
7.68%
9.43%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 16.99
DGX's Operating Margin % is ranked higher than
88% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. DGX: 16.99 )
Ranked among companies with meaningful Operating Margin % only.
DGX' s Operating Margin % Range Over the Past 10 Years
Min: 13.22  Med: 16.93 Max: 20.64
Current: 16.99
13.22
20.64
Net Margin % 8.57
DGX's Net Margin % is ranked higher than
78% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.05 vs. DGX: 8.57 )
Ranked among companies with meaningful Net Margin % only.
DGX' s Net Margin % Range Over the Past 10 Years
Min: 5.07  Med: 8.3 Max: 11.88
Current: 8.57
5.07
11.88
ROE % 13.82
DGX's ROE % is ranked higher than
81% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.21 vs. DGX: 13.82 )
Ranked among companies with meaningful ROE % only.
DGX' s ROE % Range Over the Past 10 Years
Min: 10.72  Med: 14.94 Max: 20.93
Current: 13.82
10.72
20.93
ROA % 6.38
DGX's ROA % is ranked higher than
75% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. DGX: 6.38 )
Ranked among companies with meaningful ROA % only.
DGX' s ROA % Range Over the Past 10 Years
Min: 4.78  Med: 6.64 Max: 9.31
Current: 6.38
4.78
9.31
ROC (Joel Greenblatt) % 109.19
DGX's ROC (Joel Greenblatt) % is ranked higher than
94% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. DGX: 109.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DGX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 88  Med: 116.04 Max: 143.99
Current: 109.19
88
143.99
3-Year Revenue Growth Rate 4.30
DGX's 3-Year Revenue Growth Rate is ranked higher than
53% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. DGX: 4.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DGX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 3.5  Med: 8.1 Max: 15.4
Current: 4.3
3.5
15.4
3-Year EBITDA Growth Rate -2.40
DGX's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. DGX: -2.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DGX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -2.4  Med: 9.3 Max: 44.4
Current: -2.4
-2.4
44.4
3-Year EPS without NRI Growth Rate -5.30
DGX's 3-Year EPS without NRI Growth Rate is ranked lower than
55% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.20 vs. DGX: -5.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -5.3  Med: 9.4 Max: 61.5
Current: -5.3
-5.3
61.5
GuruFocus has detected 5 Warning Signs with Quest Diagnostics Inc $DGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DGX's 10-Y Financials

Financials (Next Earnings Date: 2017-04-21)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

DGX Guru Trades in Q1 2016

John Rogers 747,094 sh (+7.77%)
Bernard Horn 61,733 sh (unchged)
John Hussman 2,000 sh (unchged)
Murray Stahl 7,350 sh (unchged)
Ray Dalio Sold Out
Jeff Auxier 69,955 sh (-0.45%)
Charles Brandes 162,685 sh (-3.73%)
Chris Davis 3,314,772 sh (-7.69%)
Joel Greenblatt 249,221 sh (-7.79%)
Scott Black 31,347 sh (-11.08%)
David Dreman 14,059 sh (-28.32%)
Paul Tudor Jones 6,786 sh (-35.67%)
Pioneer Investments 123,162 sh (-44.16%)
» More
Q2 2016

DGX Guru Trades in Q2 2016

Pioneer Investments 184,754 sh (+50.01%)
Bernard Horn 61,733 sh (unchged)
Jeff Auxier 69,955 sh (unchged)
John Hussman 2,000 sh (unchged)
Murray Stahl 7,300 sh (-0.68%)
Chris Davis 3,279,494 sh (-1.06%)
David Dreman 13,474 sh (-4.16%)
Scott Black 30,000 sh (-4.30%)
Charles Brandes 146,794 sh (-9.77%)
Paul Tudor Jones 6,000 sh (-11.58%)
Joel Greenblatt 177,438 sh (-28.80%)
John Rogers 454,535 sh (-39.16%)
» More
Q3 2016

DGX Guru Trades in Q3 2016

Lee Ainslie 37,510 sh (New)
John Hussman 76,500 sh (+3725.00%)
Joel Greenblatt 308,220 sh (+73.71%)
Paul Tudor Jones 6,000 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Pioneer Investments Sold Out
Jeff Auxier 69,530 sh (-0.61%)
Murray Stahl 7,250 sh (-0.68%)
Charles Brandes 141,534 sh (-3.58%)
David Dreman 12,702 sh (-5.73%)
Scott Black 28,269 sh (-5.77%)
John Rogers 404,984 sh (-10.90%)
Chris Davis 239,896 sh (-92.68%)
» More
Q4 2016

DGX Guru Trades in Q4 2016

Manning & Napier Advisors, Inc 7,625 sh (New)
Jim Simons 58,900 sh (New)
John Hussman 100,000 sh (+30.72%)
Charles Brandes 141,713 sh (+0.13%)
Lee Ainslie Sold Out
Paul Tudor Jones Sold Out
Murray Stahl 6,900 sh (-4.83%)
David Dreman 11,851 sh (-6.70%)
John Rogers 371,880 sh (-8.17%)
Chris Davis 203,698 sh (-15.09%)
Joel Greenblatt 234,372 sh (-23.96%)
Scott Black 21,059 sh (-25.50%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:IDXX, NYSE:LH, OTCPK:SSMXY, NYSE:A, NYSE:Q, OTCPK:ERFSF, NAS:DXCM, NAS:QGEN, OTCPK:BMXMF, NYSE:PKI, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:BRKR, NAS:PRAH, NYSE:ALR, OTCPK:CZMWY, NAS:PRXL, NAS:NEOG, NAS:EXAS » details
Traded in other countries:QDI.Germany,
Quest Diagnostics Inc is the provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions.

Quest Diagnostics Inc was incorporated in Delaware in 1990. The Company and its subsidiaries are the providers of diagnostic testing. The Company operations are organized in two business groups; Diagnostics Information Services and Diagnostic Solutions group. The Diagnostics Information Services business is a provider of diagnostic information services, which includes providing clinical testing services such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing, as well as related services and insights. The Company offers patients, physicians, hospitals, IDNs, health plans, employers and others the broadest access in the United States to diagnostic information services through its nationwide network of laboratories, Company-owned patient service centers and phlebotomists in physician offices. It provides interpretive consultation through the medical and scientific staff in the industry, including over 725 M.D.s and Ph.D.s, located in the United States, many of whom are recognized leaders in their fields, and genetic counselors. Diagnostic Solutions group offers solutions for insurers, healthcare providers and others. The Company is a provider of risk assessment services for the life insurance industry. The Company is a provider of testing for clinical trials. In addition, it offers healthcare organizations and clinicians robust information technology solutions and diagnostic products, including test kits. The Company is subject to or impacted by extensive and frequently changing laws and regulations in the United States (at both the federal and state levels) and the other jurisdictions in which it conducts business.

Top Ranked Articles about Quest Diagnostics Inc

7 Best Stocks For Value Investors This Week - 7/30/16 These companies were found and reviewed by ModernGraham
I evaluated 20 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. I also put each company through the ModernGraham valuation model based on Benjamin Graham's value investing formulas in order to determine an intrinsic value for each. Out of those 20 companies, only seven were found to be undervalued or fairly valued and suitable for either Defensive or Enterprising Investors. Read more...

Ratios

vs
industry
vs
history
PE Ratio 21.62
DGX's PE Ratio is ranked higher than
64% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. DGX: 21.62 )
Ranked among companies with meaningful PE Ratio only.
DGX' s PE Ratio Range Over the Past 10 Years
Min: 9.09  Med: 17.28 Max: 31.26
Current: 21.62
9.09
31.26
Forward PE Ratio 17.92
DGX's Forward PE Ratio is ranked higher than
71% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.08 vs. DGX: 17.92 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.62
DGX's PE Ratio without NRI is ranked higher than
63% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.37 vs. DGX: 21.62 )
Ranked among companies with meaningful PE Ratio without NRI only.
DGX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.48  Med: 15.54 Max: 22.3
Current: 21.62
9.48
22.3
Price-to-Owner-Earnings 26.58
DGX's Price-to-Owner-Earnings is ranked higher than
55% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.26 vs. DGX: 26.58 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DGX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.27  Med: 25.91 Max: 129.96
Current: 26.58
12.27
129.96
PB Ratio 2.88
DGX's PB Ratio is ranked higher than
57% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.51 vs. DGX: 2.88 )
Ranked among companies with meaningful PB Ratio only.
DGX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.46 Max: 4.31
Current: 2.88
1.85
4.31
PS Ratio 1.85
DGX's PS Ratio is ranked higher than
71% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. DGX: 1.85 )
Ranked among companies with meaningful PS Ratio only.
DGX' s PS Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.35 Max: 2.18
Current: 1.85
1.03
2.18
Price-to-Free-Cash-Flow 17.84
DGX's Price-to-Free-Cash-Flow is ranked higher than
68% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.89 vs. DGX: 17.84 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DGX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.25  Med: 13.86 Max: 21.76
Current: 17.84
8.25
21.76
Price-to-Operating-Cash-Flow 12.95
DGX's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.95 vs. DGX: 12.95 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DGX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.99  Med: 10.89 Max: 14.48
Current: 12.95
6.99
14.48
EV-to-EBIT 12.10
DGX's EV-to-EBIT is ranked higher than
78% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.75 vs. DGX: 12.10 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 10.4 Max: 15.2
Current: 12.1
7.4
15.2
EV-to-EBITDA 10.19
DGX's EV-to-EBITDA is ranked higher than
67% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.68 vs. DGX: 10.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
DGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 8.6 Max: 11.8
Current: 10.19
6.2
11.8
PEG Ratio 4.15
DGX's PEG Ratio is ranked lower than
69% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.09 vs. DGX: 4.15 )
Ranked among companies with meaningful PEG Ratio only.
DGX' s PEG Ratio Range Over the Past 10 Years
Min: 0.81  Med: 1.72 Max: 5.11
Current: 4.15
0.81
5.11
Shiller PE Ratio 24.30
DGX's Shiller PE Ratio is ranked higher than
83% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.04 vs. DGX: 24.30 )
Ranked among companies with meaningful Shiller PE Ratio only.
DGX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.47  Med: 19.86 Max: 37.46
Current: 24.3
14.47
37.46
Current Ratio 1.56
DGX's Current Ratio is ranked lower than
75% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.70 vs. DGX: 1.56 )
Ranked among companies with meaningful Current Ratio only.
DGX' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 1.26 Max: 1.94
Current: 1.56
0.89
1.94
Quick Ratio 1.48
DGX's Quick Ratio is ranked lower than
70% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. DGX: 1.48 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.19 Max: 1.83
Current: 1.48
0.82
1.83
Days Inventory 6.48
DGX's Days Inventory is ranked higher than
93% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 75.58 vs. DGX: 6.48 )
Ranked among companies with meaningful Days Inventory only.
DGX' s Days Inventory Range Over the Past 10 Years
Min: 6.48  Med: 7.69 Max: 8.46
Current: 6.48
6.48
8.46
Days Sales Outstanding 44.98
DGX's Days Sales Outstanding is ranked higher than
78% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. DGX: 44.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.51  Med: 43.71 Max: 48.01
Current: 44.98
40.51
48.01
Days Payable 20.64
DGX's Days Payable is ranked lower than
86% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.14 vs. DGX: 20.64 )
Ranked among companies with meaningful Days Payable only.
DGX' s Days Payable Range Over the Past 10 Years
Min: 16.4  Med: 18.43 Max: 21.87
Current: 20.64
16.4
21.87

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.70
DGX's Dividend Yield % is ranked higher than
74% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. DGX: 1.70 )
Ranked among companies with meaningful Dividend Yield % only.
DGX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.6  Med: 0.85 Max: 2.46
Current: 1.7
0.6
2.46
Dividend Payout Ratio 0.45
DGX's Dividend Payout Ratio is ranked lower than
70% of the 56 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. DGX: 0.45 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DGX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.17 Max: 0.45
Current: 0.45
0.1
0.45
3-Year Dividend Growth Rate 10.60
DGX's 3-Year Dividend Growth Rate is ranked higher than
50% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.60 vs. DGX: 10.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DGX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 5.5 Max: 55.4
Current: 10.6
0
55.4
Forward Dividend Yield % 1.85
DGX's Forward Dividend Yield % is ranked higher than
71% of the 89 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.13 vs. DGX: 1.85 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 7.22
DGX's 5-Year Yield-on-Cost % is ranked higher than
97% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. DGX: 7.22 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DGX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.53  Med: 3.59 Max: 10.39
Current: 7.22
2.53
10.39
3-Year Average Share Buyback Ratio 1.60
DGX's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. DGX: 1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.9  Med: 1.6 Max: 7
Current: 1.6
-16.9
7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.27
DGX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. DGX: 1.27 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DGX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.71  Med: 0.89 Max: 2.6
Current: 1.27
0.71
2.6
Price-to-Intrinsic-Value-DCF (Earnings Based) 2.02
DGX's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
63% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.75 vs. DGX: 2.02 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.37
DGX's Price-to-Median-PS-Value is ranked lower than
68% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. DGX: 1.37 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DGX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.03 Max: 1.48
Current: 1.37
0.24
1.48
Price-to-Peter-Lynch-Fair-Value 4.19
DGX's Price-to-Peter-Lynch-Fair-Value is ranked lower than
79% of the 24 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.71 vs. DGX: 4.19 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
DGX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.7  Med: 1.41 Max: 4.19
Current: 4.19
0.7
4.19
Earnings Yield (Greenblatt) % 8.30
DGX's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. DGX: 8.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DGX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 6.6  Med: 9.6 Max: 13.6
Current: 8.3
6.6
13.6
Forward Rate of Return (Yacktman) % 9.97
DGX's Forward Rate of Return (Yacktman) % is ranked higher than
57% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.86 vs. DGX: 9.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DGX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 9.97  Med: 14.7 Max: 25.8
Current: 9.97
9.97
25.8

More Statistics

Revenue (TTM) (Mil) $7,515
EPS (TTM) $ 4.50
Beta0.91
Short Percentage of Float3.46%
52-Week Range $65.06 - 97.35
Shares Outstanding (Mil)137.50

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 7,667 7,807 7,977
EPS ($) 5.42 5.68 6.14
EPS without NRI ($) 5.42 5.68 6.14
EPS Growth Rate
(Future 3Y To 5Y Estimate)
5.78%
Dividends per Share ($) 1.72 1.85 2.10
» More Articles for DGX

Headlines

Articles On GuruFocus.com
3 Dividend Stocks for 2017 Feb 13 2017 
6 Stocks With High Business Predictability Jan 31 2017 
7 Profitable Companies With Strong Yields Jan 10 2017 
A Solid 13% Dividend Increase, Compelling Valuation Nov 28 2016 
6 Stocks to Watch Oct 04 2016 
7 Best Stocks For Value Investors This Week - 7/30/16 Aug 01 2016 
Companies Hit 52-Week Highs Jul 19 2016 
Royce Special Equity Multi-Cap Fund Mar 22 2016 
Baron Growth Fund New Purchases Part 3 Feb 08 2016 
Popular Guru Stocks With High, Growing Yield Feb 03 2016 

More From Other Websites
QUEST DIAGNOSTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 24 2017
Quest Diagnostics Declares Quarterly Cash Dividend Feb 21 2017
Quest Diagnostics Named One of 2017 "World's Most Admired Companies" by Fortune Magazine Feb 16 2017
Quest Diagnostics: Harvard Pilgrim Health Care Partners with Physicians to Close Costly Gaps in Care Feb 16 2017
Quest Diagnostics and PeaceHealth to Increase Access to Innovative, High-Value Laboratory Services... Feb 15 2017
3 Dividend Stocks for 2017 Feb 13 2017
Quest Diagnostics Partners with Veracyte for Cancer Testing Feb 09 2017
Veracyte to Expand Patient Access to the Afirma® Gene Expression Classifier In Thyroid Cancer... Feb 08 2017
ETFs with exposure to Quest Diagnostics, Inc. : February 2, 2017 Feb 02 2017
Quest Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : DGX-US : January... Jan 31 2017
Quest Diagnostics, Inc. :DGX-US: Earnings Analysis: 2016 By the Numbers : January 30, 2017 Jan 30 2017
Edited Transcript of DGX earnings conference call or presentation 26-Jan-17 1:30pm GMT Jan 26 2017
Quest Diagnostics (DGX) Tops Q4 Earnings, Offers '17 View Jan 26 2017
Quest Diagnostics Inc Earnings Call scheduled for 8:30 am ET today Jan 26 2017
Quest Diagnostics (DGX): Tops Q4 Earnings, Sales in Line Jan 26 2017
Quest Diagnostics tops 4Q profit forecasts Jan 26 2017
Quest Diagnostics tops 4Q profit forecasts Jan 26 2017
Q4 2016 Quest Diagnostics Inc Earnings Release - Before Market Open Jan 26 2017
QUEST DIAGNOSTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 26 2017
Quest Diagnostics Reports Fourth Quarter And Full Year 2016 Financial Results; Provides Guidance For... Jan 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)